Floatz logo

AUTOLOGOUS PBL

Metastatic Cutaneous Melanoma

National Cancer Institute (NCI)Cell therapyPhase 2Dormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

152 Active assets in the Metastatic Cutaneous Melanoma cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB

View all 50 →

Same molecule, other indications

AUTOLOGOUS PBL is also rated in:

metastatic melanomaDormant
D
Indicative ·
30 / 100
View asset →
Stage III MelanomaDormant
D
Indicative ·
30 / 100
View asset →
skin cancerDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →